Evidence map›Paper›PMID 41168504›Full record

ReviewAAPS PharmSciTech2025

Injectables Protein-Based Nanodiscs in Cancer Drug Delivery: From Bench to Clinical Potential.

Vimal Patel, Jigar N Shah, Saloni Dalwadi, Parv Barot, Darshan Vaghela, Megha Patel, Vijaykumar Sutariya

Abstract readReview
PubMed Publisher
In one paragraph

Review in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Vimal PatelDepartment of Pharmaceutics, School of Pharmacy, P P Savani University, Surat, 394125, Gujarat, India.ORCID http://orcid.org/0000-0002-4774-0159
Jigar N ShahDepartment of Pharmaceutics, Institute of Pharmacy, Nirma University, Ahmedabad, 382481, Gujarat, India. jigar.shah@nirmauni.ac.in.ORCID http://orcid.org/0000-0002-9375-528X
Saloni DalwadiDepartment of Pharmaceutics, Anand Pharmacy College, Anand, 388001, Gujarat, India.ORCID http://orcid.org/0000-0003-3643-6001
Parv BarotJane Anne Nohl Division of Hematology and Center for the Study of Blood Disease, Division of Hematology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA, USA.ORCID http://orcid.org/0009-0006-3179-9937
Darshan VaghelaCrop Biotechnology Research Lab, Department of Bioscience and Bioengineering, IIT-Guwahati, Assam, 781039, India.ORCID http://orcid.org/0000-0003-4788-6104
Megha PatelDepartment of Biological Sciences, St. John's College of Liberal Arts and Sciences, St. John's University, Queens, New York, 11432, USA.ORCID http://orcid.org/0009-0000-3978-7339
Vijaykumar SutariyaDepartment of Pharmaceutical Sciences, USF Health Taneja College of Pharmacy, University of South Florida, Tampa, Florida, 33620, USA.ORCID http://orcid.org/0000-0001-8998-2298

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Membrane mimicking protein nanodiscs are nanoscale structures composed of a lipid bilayer and a scaffold protein that forms a circular disc-like structure. These NDs are designed to mimic the natural cell membrane and are used as a platform to study membrane-associated proteins, such as those involved in signal transduction or drug transport. In cancer therapeutics, NDs have been developed as a promising nano-formulation for delivering macromolecules, such as drugs or nucleic acids, to cancer cells. The NDs can be functionalized with targeting ligands, such as antibodies or peptides, to specifically bind to cancer cells and deliver therapeutic payloads. One advantage of ND-based formulations is their ability to protect macromolecules from degradation and enhance their pharmacokinetics and bioavailability. Additionally, the use of NDs as a delivery vehicle allows for the precise control of drug release, which can improve efficacy while reducing toxic side effects. Overall, membrane mimicking protein NDs show great potential as a versatile platform for macromolecular delivery in cancer therapeutics, with the ability to precisely target cancer cells and enhance the therapeutic effect of drugs or nucleic acids. In this review, we discuss the structural components, stability issues, synthetic strategies, limitations, therapeutic advancements, and future challenges associated with the clinical implication of ND's anti-cancer therapies.

Indexed as

Antineoplastic AgentsDrug Delivery SystemsNanoparticlesNanostructuresNeoplasmsProteinsAnimalsDrug CarriersHumansLipid BilayersAntineoplastic AgentsDrug CarriersLipid BilayersProteinsCancer therapeuticsClinical trialsMembrane mimicking nanodiscPersonalized medicines

Identifiers

PMID41168504

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.